Leadership: Page 10


  • patient care
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A

    Why patient care is a public affair

    The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.

    By Feb. 23, 2023
  • Michelle Werner Alltrna
    Image attribution tooltip
    Permission granted by Michelle Werner Alltrna
    Image attribution tooltip
    Podcast

    Woman of the Week: Alltrna’s Michelle Werner

    The first-time CEO has her sights on addressing thousands of diseases with the company’s tRNA platform.

    By Feb. 22, 2023
  • drug shopping cart Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Commercialization, marketing and social media

    As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

    By PharmaVoice staff
  • Two grey haired women sit on a bench eating ice cream
    Image attribution tooltip
    Peter Macdiarmid/Getty Images via Getty Images
    Image attribution tooltip
    Profile

    Tapping into the molecular fountain of youth

    Kristen Fortney, CEO of BioAge Labs, wants to improve the human life span by focusing on the human health span.

    By Alexandra Pecci • Feb. 22, 2023
  • vaccine vial
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies

    Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.

    By Feb. 17, 2023
  • Cancer antibodies
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

    The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.

    By Feb. 16, 2023
  • Ester Banque Bristol Myers Squibb
    Image attribution tooltip
    Permission granted by Ester Banque Bristol Myers Squibb
    Image attribution tooltip
    Podcast

    Woman of the Week: Bristol Myers Squibb’s Ester Banque

    The 30-year veteran is heading up the “transformation” of one of the pharma giant’s most important therapeutic portfolios: hematology.

    By Feb. 15, 2023
  • Will Chou headshot
    Image attribution tooltip
    Permission granted by Dr. William Chou, Passage Bio
    Image attribution tooltip
    Q&A

    Managing for resilience: Passage’s ups and downs in gene therapy

    After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.

    By Feb. 15, 2023
  • Professional headshot of Brian Fox
    Image attribution tooltip
    Permission granted by Klick Group
    Image attribution tooltip
    Q&A // First 90 Days

    Brian Fox is bringing ‘fresh eyes’ to ad agency Klick

    Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.

    By Karissa Waddick • Feb. 13, 2023
  • The logo of German pharmaceuticals and chemicals giant Bayer stands over Bayer corporate offices on September 14, 2016 in Berlin, Germany.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip
    Making Moves

    Bayer, Astellas switch CEOs amid major inflection points

    Bayer’s Bill Anderson and Astellas’ Naoki Okamura will be charged with setting the companies on growth trajectories for 2023.

    By Karissa Waddick • Feb. 9, 2023
  • Vlad Coric
    Image attribution tooltip
    Permission granted by Biohaven
    Image attribution tooltip
    Profile

    The unique playbook of Biohaven’s CEO

    Vlad Coric’s offbeat business strategy paid off once with a Pfizer buyout. Can he do it again?

    By Feb. 8, 2023
  • Helena Chaye KaliVir Immunotherapeutics
    Image attribution tooltip
    Permission granted by Helena Chaye KaliVir Immunotherapeutics
    Image attribution tooltip
    Podcast

    Woman of the Week: KaliVir Immunotherapeutics’ Helena Chaye

    The triple threat CEO — scientist, lawyer and biotech pro — thinks she’s discovered a key to curing a wide range of cancers.

    By Feb. 8, 2023
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Making Moves

    Roche, Chiesi and the FDA change major leadership roles as they strive for growth in 2023

    From Roche’s new pharma chief to the departure of the FDA’s gene therapy head, these moves are bound to shake up the industry.

    By Karissa Waddick • Feb. 6, 2023
  • Victoria Richon
    Image attribution tooltip
    Permission granted by Entact Bio
    Image attribution tooltip
    Q&A // First 90 Days

    Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement

    Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.

    By Kelly Bilodeau • Feb. 6, 2023
  • Pfizer CEO Albert Burl and company executives
    Image attribution tooltip
    Drew Angerer via Getty Images
    Image attribution tooltip

    Execs at Pfizer, Novartis, Amgen and GSK tackle shifting priorities — reflecting the state of Big Pharma

    A menagerie of earnings calls this week showed where the Big Pharma players stand in 2023.

    By Feb. 2, 2023
  • Yesmean Wahdan Bayer
    Image attribution tooltip
    Permission granted by Yesmean Wahdan Bayer
    Image attribution tooltip
    Podcast

    Woman of the Week: Bayer’s Dr. Yesmean Wahdan

    The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.

    By Feb. 1, 2023
  • Marc de Garidel, CEO, CinCor
    Image attribution tooltip
    Permission granted by CinCor
    Image attribution tooltip
    Q&A

    This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic

    With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.

    By Jan. 31, 2023
  • Johanna Mercier headshot
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip
    Q&A

    Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

    With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

    By Jan. 26, 2023
  • J&J CEO Joaquin Duato
    Image attribution tooltip
    Mike Coppola via Getty Images
    Image attribution tooltip

    Economic crisis? J&J execs say that won’t stop them from hitting $60B target

    The pharma giant's CEO Joaquin Duato and CFO Joseph Wolk showed that they're optimistic about reaching lofty goals despite hard economic times.

    By Jan. 25, 2023
  • Lauren Lazar Calcium
    Image attribution tooltip
    Permission granted by Lauren Lazar Calcium
    Image attribution tooltip
    Podcast

    Woman of the Week: Dr. Lauren Lazar

    As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.

    By Jan. 25, 2023
  • Talia Cohen-Solal Genetika+
    Image attribution tooltip
    Permission granted by Talia Cohen-Solal WoW
    Image attribution tooltip
    Podcast

    Woman of the Week: Genetika+’s Talia Cohen Solal

    The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.

    By Jan. 18, 2023
  • M&A handshake
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Biopharma M&A may get the push it needs in 2023, but with a face lift

    A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.

    By Jan. 12, 2023
  • A photograph of a Biogen building located in Cambridge, Massachusetts, on Oct. 22, 2015.
    Image attribution tooltip

    Nicolaus Czarnecki/Zuma Press/Newscom

    Image attribution tooltip
    Making Moves

    C-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans

    A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.

    By Karissa Waddick • Jan. 10, 2023
  • Kidney
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Chinook Therapeutics nears the finish line in kidney disease

    A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.

    By Jan. 10, 2023
  • Karate
    Image attribution tooltip
    grapix via Getty Images
    Image attribution tooltip

    The kindred nature of martial arts and drug development

    How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.

    By Alexandra Pecci • Jan. 9, 2023
  • An aerial view of San Francisco
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    What’s top of mind for industry execs at JPM?

    Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.

    By Jan. 6, 2023